Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey
- PMID: 19952801
- DOI: 10.1097/JTO.0b013e3181c5920c
Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey
Abstract
Introduction: We examined the recent changes in stage distribution in newly diagnosed patients with non-small cell lung cancer (NSCLC) using a national database to assess the impact of recent advances in imaging modalities.
Methods: We searched the National Cancer Database for patients with NSCLC diagnosed between the calendar years 1998 and 2006 for which staging information was available.
Results: Among the 877,518 patients diagnosed with NSCLC during the study period, staging information was available for 813,302 patients (92.6%). We observed a change in stage distribution between the years 2000 and 2001, with a decrease in stage I, from 27.5 to 24.8%, and a corresponding increase in stage IV, from 35.4 to 38.8%. No significant changes in stage distribution were noted after 2002.
Conclusion: Our study showed a recent and significant stage migration in patients with NSCLC. It is likely that increased acceptance and widespread use of (18)fluorodeoxyglucose-positron emission tomography scan and routine brain imaging could account for these changes.
Similar articles
-
The effect of FDG-PET on the stage distribution of non-small cell lung cancer.J Thorac Oncol. 2008 Feb;3(2):135-9. doi: 10.1097/JTO.0b013e3181622c2c. J Thorac Oncol. 2008. PMID: 18303433
-
Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.Clin Lung Cancer. 2014 Jan;15(1):79-85. doi: 10.1016/j.cllc.2013.08.004. Epub 2013 Oct 8. Clin Lung Cancer. 2014. PMID: 24238934 Clinical Trial.
-
Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.Eur J Cancer. 2015 Nov;51(17):2534-44. doi: 10.1016/j.ejca.2015.08.008. Epub 2015 Aug 28. Eur J Cancer. 2015. PMID: 26323530
-
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.J Thorac Oncol. 2007 Jun;2(6):499-505. doi: 10.1097/JTO.0b013e3180600990. J Thorac Oncol. 2007. PMID: 17545844
-
Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003.J Thorac Oncol. 2012 Oct;7(10):1479-84. doi: 10.1097/JTO.0b013e318267d032. J Thorac Oncol. 2012. PMID: 22982648
Cited by
-
Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001.Transl Lung Cancer Res. 2021 Feb;10(2):712-722. doi: 10.21037/tlcr-20-721. Transl Lung Cancer Res. 2021. PMID: 33718016 Free PMC article.
-
Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer.Cancers (Basel). 2020 Jun 18;12(6):1619. doi: 10.3390/cancers12061619. Cancers (Basel). 2020. PMID: 32570944 Free PMC article.
-
Management of Combined Therapy (Ceritinib, A. cinnamomea, G. lucidum, and Photobiomodulation) in Advanced Non-Small-Cell Lung Cancer: A Case Report.Life (Basel). 2022 Jun 9;12(6):862. doi: 10.3390/life12060862. Life (Basel). 2022. PMID: 35743893 Free PMC article.
-
FOXM1/lncRNA TYMSOS/miR-214-3p-Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non-Small Cell Lung Carcinoma.Front Mol Biosci. 2022 Feb 8;8:785767. doi: 10.3389/fmolb.2021.785767. eCollection 2021. Front Mol Biosci. 2022. PMID: 35211508 Free PMC article.
-
The Roles of MicroRNA in Lung Cancer.Int J Mol Sci. 2019 Mar 31;20(7):1611. doi: 10.3390/ijms20071611. Int J Mol Sci. 2019. PMID: 30935143 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical